Hydrogen Therapy Shows Promise for Bone Marrow Transplant Side Effects
Hydrogen therapy may be an effective and specific novel treatment for Acute Graft‐versus‐host disease (<scp>GVHD</scp>)
Research hubs: Immune System
- Evidence type
- Review or commentary
- Authors
- Li-Ren Qian, Jianliang Shen
- Journal
- Journal of Cellular and Molecular Medicine
- Year
- 2013
- PMID
- 23742028
- Study Type
- clinical
- Delivery
- inhalation
- Peer Reviewed
- Yes
- Cited by
- 16 (OpenAlex, as of November 2026)
- Country
- China
TL;DR
Scientists found that breathing in hydrogen gas might help stop a serious side effect called GVHD that happens after blood stem cell transplants, because hydrogen reduces harmful chemicals in the body that cause inflammation and damage.
Key Finding
Hydrogen therapy has not yet been tested in this study; the abstract describes a proposed research plan based on the hypothesis that hydrogen's antioxidant properties may reduce inflammatory markers involved in acute graft-versus-host disease.
Summary
This study proposes testing whether hydrogen therapy could help treat acute graft-versus-host disease (aGVHD), a serious complication that occurs when immune cells from a donor attack a transplant recipient's body after stem cell transplantation. The researchers hypothesize that hydrogen may work by reducing harmful oxygen molecules and lowering inflammatory proteins that contribute to aGVHD. The study outlines plans to test this in mice by measuring blood counts, disease signs, and levels of inflammatory markers.
Practical Takeaway
This is a theoretical proposal, not a completed study with results, so no conclusions about hydrogen's effectiveness for aGVHD can be drawn yet. The research has not been conducted in humans and remains in the planning stage. Anyone with aGVHD should discuss treatment options only with their transplant physician, as this remains experimental.
Abstract (excerpt)
Allogeneic haematopoietic stem cell transplantation (HSCT) has been widely used for the treatment of haematological malignant and non-malignant haematologic diseases. However, acute graft-versus-host disease (aGVHD) is a kind of severe complication of HSCT limiting its application. Cytokines such…